Herantis Pharma Oyj (HRPMF)
Herantis Pharma Oyj operates in the Biotechnology industry of the Healthcare sector, headquartered in Espoo, FI. The stock last traded at $3.51, up 0.00% on the session, giving a market capitalisation of $59.5M. On trailing twelve-month figures it carries a trailing P/E of -5.19, a net margin of 0.0%. Its beta of 0.43 implies it has historically moved less than the broad market.
Herantis Pharma Oyj, a biotechnology enterprise, specializes in creating disease-modifying therapies for Parkinson's disease (PD) that harness Cerebral Dopamine Neurotrophic Factor (CDNF). Central to its developmental efforts is HER-096, a sophisticated, compact, synthetic chemical peptidomimetic originating from the active parent molecule. This preclinical xCDNF candidate is currently being investigated for its therapeutic promise in PD and other neurodegenerative conditions. Additionally, the firm is advancing recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is presently undergoing Phase I clinical evaluation in individuals afflicted with Parkinson's. Founded in 2008, Herantis Pharma Oyj maintains its corporate headquarters in Espoo, Finland.
Herantis Pharma Oyj is most often compared with the following Healthcare names: